DK2919796T3 - Brug af akkermansia til behandling af stofskiftesygdomme - Google Patents

Brug af akkermansia til behandling af stofskiftesygdomme Download PDF

Info

Publication number: DK2919796T3
Authority: DK; Denmark
Prior art keywords: metable; akkermansia; diseases; treatment; metable diseases
Prior art date: 2012-11-19

Application number

DK13792006.2T

Other languages

English (en)

Inventor

Clara Belzer

Vos Willem De

Patrice Cani

Amandine Everard

Original Assignee

Univ Catholique Louvain

Univ Wageningen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-19

Filing date

2013-11-15

Publication date

2021-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47257788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2919796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-15 Application filed by Univ Catholique Louvain, Univ Wageningen filed Critical Univ Catholique Louvain

2021-05-31 Application granted granted Critical

2021-05-31 Publication of DK2919796T3 publication Critical patent/DK2919796T3/da

Links

0 C*(*)(*)CC1*CC(*)C1 Chemical compound C*(*)(*)CC1*CC(*)C1 0.000 description 1
JKKHRLLTWYVLJP-UHFFFAOYSA-N COCC(C(CN=O)N)OC Chemical compound COCC(C(CN=O)N)OC JKKHRLLTWYVLJP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)

DK13792006.2T 2012-11-19 2013-11-15 Brug af akkermansia til behandling af stofskiftesygdomme DK2919796T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/EP2012/073011 WO2014075745A1 (en)	2012-11-19	2012-11-19	Use of akkermansia for treating metabolic disorders
PCT/EP2013/073972 WO2014076246A1 (en)	2012-11-19	2013-11-15	Use of akkermansia for treating metabolic disorders

Publications (1)

Publication Number	Publication Date
DK2919796T3 true DK2919796T3 (da)	2021-05-31

Family

ID=47257788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13792006.2T DK2919796T3 (da)	2012-11-19	2013-11-15	Brug af akkermansia til behandling af stofskiftesygdomme

Country Status (14)

Country	Link
US (10)	US20150306152A1 (da)
JP (2)	JP6426616B2 (da)
KR (7)	KR20210111871A (da)
CN (2)	CN111603488B (da)
AU (1)	AU2013346726B2 (da)
BR (1)	BR112015011403A2 (da)
CA (1)	CA2891758C (da)
DK (1)	DK2919796T3 (da)
EA (2)	EA202100040A3 (da)
ES (3)	ES3037446T3 (da)
MX (1)	MX365835B (da)
PL (1)	PL3862010T3 (da)
PT (1)	PT2919796T (da)
WO (2)	WO2014075745A1 (da)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201112091D0 (en)	2011-07-14	2011-08-31	Gt Biolog Ltd	Bacterial strains isolated from pigs
GB201117313D0 (en)	2011-10-07	2011-11-16	Gt Biolog Ltd	Bacterium for use in medicine
US9173910B2 (en)	2012-02-29	2015-11-03	The General Hospital Corporation	Compositions of microbiota and methods related thereto
WO2013139861A1 (en)	2012-03-20	2013-09-26	Luc Montagnier	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014075745A1 (en) *	2012-11-19	2014-05-22	Université Catholique de Louvain	Use of akkermansia for treating metabolic disorders
GB201306536D0 (en)	2013-04-10	2013-05-22	Gt Biolog Ltd	Polypeptide and immune modulation
US10633714B2 (en)	2013-07-21	2020-04-28	Pendulum Therapeutics, Inc.	Methods and systems for microbiome characterization, monitoring and treatment
US20150246081A1 (en) *	2014-03-03	2015-09-03	Shayne Kenneth Morris	Probiotics with methods for growth and use separately and in combination
KR101740893B1 (ko)	2014-05-20	2017-06-13	주식회사 엠디헬스케어	Ａｋｋｅｒｍａｎｓｉａｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
CN113730442A (zh) *	2014-10-31	2021-12-03	潘德勒姆治疗公司	与病症的微生物治疗和诊断有关的方法和组合物
SMT201800291T1 (it)	2014-12-23	2018-07-17	4D Pharma Res Limited	Polipeptide pirina e modulazione immunitaria
SG10201913609PA (en)	2014-12-23	2020-03-30	4D Pharma Res Ltd	Immune modulation
EP3292134B1 (en)	2015-05-06	2020-10-21	Wageningen Universiteit	Method of culturing akkermansia
EA201700507A1 (ru)	2015-05-06	2018-05-31	Университе Католик Де Лувен	Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
MA41010B1 (fr)	2015-06-15	2020-01-31	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
RS59446B1 (sr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
SMT201900539T1 (it)	2015-06-15	2019-11-13	4D Pharma Res Limited	Composizioni comprendenti ceppi batterici
MA41060B1 (fr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
EP3360559B1 (en)	2015-06-15	2019-10-23	4D Pharma Research Limited	Compositions comprising bacterial strains
CN105106245A (zh) *	2015-08-24	2015-12-02	上海交通大学医学院附属瑞金医院	Akkermansia muciniphila BAA-835菌株的应用
CN105030841A (zh) *	2015-08-24	2015-11-11	上海交通大学医学院附属瑞金医院	Akkermansia muciniphila BAA-835菌株的应用
CN108289918B (zh) *	2015-09-10	2022-01-18	卢万天主教大学	经巴氏灭菌的艾克曼菌用于治疗代谢病症的用途
JP2018534277A (ja)	2015-10-05	2018-11-22	シュヴァイツェリッシェフォルシュングスインスティテュートフュアホーフゲブリクスクリーマウントメディツィンインダヴォス	炎症性状態を治療するためのアッカーマンシア・ムシニフィラ（Ａｋｋｅｒｍａｎｓｉａｍｕｃｉｎｉｐｈｉｌａ）の使用
WO2017060491A1 (en) *	2015-10-09	2017-04-13	Biogaia Ab	Mucus thickness to prevent diseases
CN105176822B (zh) *	2015-10-23	2019-01-11	广州康泽医疗科技有限公司	一种人类肠道益生菌的优化分离方法
CA3005781C (en)	2015-11-20	2019-01-22	4D Pharma Research Limited	Compositions comprising bacterial strains
GB201520497D0 (en)	2015-11-20	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520631D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520638D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
CN116570631A (zh)	2016-02-04	2023-08-11	根特大学	微生物群落用于人类和动物健康的用途
CA3016179C (en)	2016-03-04	2019-08-13	4D Pharma Plc	Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en)	2016-07-13	2016-08-24	4D Pharma Plc	Compositions comprising bacterial strains
AU2017228502C1 (en) *	2016-03-04	2021-09-16	The Regents Of The University Of California	Microbial consortium and uses thereof
DK3443071T3 (da)	2016-04-11	2022-01-31	Univ Wageningen	Hidtil ukendt bakterieart
GB201609811D0 (en)	2016-06-05	2016-07-20	Snipr Technologies Ltd	Methods, cells, systems, arrays, RNA and kits
EP3483256A4 (en) *	2016-07-11	2019-12-04	Korea Research Institute of Bioscience and Biotechnology	AKKERMANSIA MUCINIPHILA TRIBE WITH EFFECT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES OR METABOLIC DISEASES AND USE THEREOF
TWI802545B (zh)	2016-07-13	2023-05-21	英商４Ｄ製藥有限公司	包含細菌菌株之組合物
CN109874329B (zh) *	2016-08-12	2023-08-29	深圳华大生命科学研究院	一种产丁酸栖粪杆菌及其培养方法和应用
GB201621123D0 (en)	2016-12-12	2017-01-25	4D Pharma Plc	Compositions comprising bacterial strains
EP3558329B1 (en) *	2016-12-20	2024-01-31	The Regents of The University of California	Compositions and methods for inhibiting seizures
EP3606325B1 (en)	2017-04-03	2024-09-04	Gusto Global, LLC	Rational design of microbial-based biotherapeutics
FR3065643B1 (fr)	2017-04-26	2020-04-17	Usines Chimiques D'ivry La Bataille (Ucib)	Composition nutraceutique et/ou pharmaceutique pour stimuler la production de beta-defensines de type 2
US10695386B2 (en)	2017-05-11	2020-06-30	Shayne K. Morris	Skin microbiome colonizer formulations and methods for use
TW201907929A (zh)	2017-05-22	2019-03-01	英商4D製藥研究有限公司	包含細菌品系之組成物
TW201907931A (zh)	2017-05-24	2019-03-01	英商4D製藥研究有限公司	包含細菌菌株之組合物
LT3638271T (lt)	2017-06-14	2021-01-11	4D Pharma Research Limited	Kompozicijos, apimančios bakterines padermes
PL3600363T3 (pl)	2017-06-14	2021-06-14	4D Pharma Research Limited	Kompozycje zawierające szczepy bakteryjne
WO2018229236A2 (en)	2017-06-14	2018-12-20	4D Pharma Research Limited	Compositions comprising bacterial strains
TWI640314B (zh) *	2017-08-22	2018-11-11	長庚生物科技股份有限公司	戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
TWI636788B (zh) *	2017-08-28	2018-10-01	長庚生物科技股份有限公司	戈氏副擬桿菌用於抑制脂肪肝疾病之用途
WO2019046646A1 (en)	2017-08-30	2019-03-07	Whole Biome Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP7171602B2 (ja) *	2017-11-08	2022-11-15	アサヒグループホールディングス株式会社	アッカーマンシア・ムシニフィラ増殖材
EP3716983A4 (en) *	2017-11-30	2022-03-02	Glycom A/S	HUMAN MILK OLIGOSACCHARIDES AND SYNTHETIC COMPOSITIONS THEREOF FOR MICROBIOTA MODULATION
US11534465B2 (en) *	2018-03-02	2022-12-27	Academisch Medisch Centrum	Fecal matter for treatment of autoimmune diseases
WO2019199895A1 (en)	2018-04-10	2019-10-17	Siolta Therapeutics, Inc.	Microbial consortia
US11168299B2 (en)	2018-04-11	2021-11-09	Shayne Morris	Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en)	2018-04-11	2022-04-05	Shayne Morris	Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
KR102225939B1 (ko) *	2018-04-19	2021-03-10	주식회사 고바이오랩	신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
EP3802788B1 (en)	2018-05-15	2025-07-02	Duke University	Systems and methods for genetic manipulation of akkermansia species
CN110496140B (zh) *	2018-05-18	2022-05-31	瑞微（深圳）生物科技有限公司	脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用
US12292445B2 (en)	2018-05-23	2025-05-06	The Regents Of The University Of California	Methods of selecting subjects for treatment with metabolomic modulators
EP3594321A1 (en) *	2018-07-10	2020-01-15	Université catholique de Louvain	Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
EP3823651A4 (en)	2018-07-19	2022-04-27	Pendulum Therapeutics, Inc.	METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
CA3109264A1 (en) *	2018-08-20	2020-02-27	Murdoch Children's Research Institute	Behavioural treatment
CN110964650B (zh) *	2018-09-27	2022-10-11	上海上药信谊药厂有限公司	一种用于预防和治疗代谢疾病的菌株及其应用
KR102377407B1 (ko) *	2018-10-01	2022-03-22	한국생명공학연구원	아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물
KR102197180B1 (ko) *	2018-10-11	2020-12-31	주식회사 고바이오랩	아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
WO2020076136A2 (ko) *	2018-10-11	2020-04-16	서울대학교산학협력단	아커만시아 뮤시니필라 균주 및 이의 용도
EP3669944B1 (en) *	2018-12-21	2023-12-20	Salomon Amar	Use of akkermansia in the treatment of oral diseases
WO2020221899A1 (en) *	2019-05-02	2020-11-05	Université Catholique de Louvain	Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
JP7402629B2 (ja) *	2019-07-19	2023-12-21	国立大学法人東京農工大学	プロピオン酸菌発酵物含有組成物
TWI719549B (zh) *	2019-07-22	2021-02-21	大江生醫股份有限公司	促進嗜黏蛋白艾克曼菌生長之益生質組合物
KR102128287B1 (ko) *	2019-08-23	2020-06-30	주식회사 엔테로바이옴	아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
KR102128289B1 (ko) *	2019-08-23	2020-06-30	주식회사 엔테로바이옴	아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
EP4079837A4 (en) *	2019-09-25	2024-06-05	HealthBiome, Inc.	OBLIGATE ANAEROBIC HUMAN INTESTINAL MICROBES FOR CANCER TREATMENT AND ITS USE
KR102397916B1 (ko) *	2019-10-01	2022-05-17	(주)헬스바이옴	건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN114786690A (zh)	2019-10-07	2022-07-22	谢尔塔治疗公司	治疗性药物组合物
CN110698547B (zh) *	2019-10-31	2023-01-03	南京农业大学	重组表达的阿克曼菌膜蛋白Amuc_1100及其应用
CN110786376A (zh) *	2019-11-07	2020-02-14	中南大学湘雅医院	嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用
CN111202752A (zh) *	2020-02-17	2020-05-29	上海市内分泌代谢病研究所	阿克曼氏菌组合物
CN111228315A (zh)	2020-02-27	2020-06-05	上海上药信谊药厂有限公司	抗肿瘤组合物
CN111450233B (zh) *	2020-03-19	2021-04-13	中国农业大学	一种微生物代谢产物在缓解糖脂代谢紊乱中的应用
CN115666627A (zh) *	2020-03-25	2023-01-31	韩国生命工学研究院	源自嗜黏蛋白阿克曼菌的tars或其片段，及其用途
EP4125441A2 (en) *	2020-04-03	2023-02-08	DuPont Nutrition Biosciences ApS	Composition comprising bacterial strains for improving metabolic health
WO2021215828A1 (ko) *	2020-04-24	2021-10-28	주식회사 고바이오랩	Glp-1 유도 활성을 갖는 단백질 변이체 및 이의 용도
CN111996267A (zh) *	2020-08-11	2020-11-27	康美华大基因技术有限公司	一种快速检测akk菌的荧光定量pcr引物组、试剂盒及其应用
KR102185827B1 (ko) *	2020-08-26	2020-12-03	주식회사 엔테로바이옴	아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
BE1028339B1 (fr) *	2020-11-09	2021-12-21	A Mansia Biotech	Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CN113116936A (zh) *	2021-04-02	2021-07-16	上海市第六人民医院	嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用
CN113322202B (zh) *	2021-05-31	2022-03-01	君维安(武汉)生命科技有限公司	一种阿克曼氏菌、其培养方法及其应用
KR102380194B1 (ko) *	2021-06-11	2022-03-29	쿼럼바이오 주식회사	갈락토오스를 포함하는 장내 미생물 개체군 개선용 조성물
JP7398714B2 (ja) *	2021-06-28	2023-12-15	東栄新薬株式会社	医療・美容に応用可能なアッカーマンシア・ムシニフィラ増殖促進用組成物およびこれを含む医薬、飲食品、飼料
CN113862193B (zh) *	2021-10-28	2023-12-22	江西普瑞森基因科技有限公司	一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用
WO2023086620A1 (en) *	2021-11-12	2023-05-19	Gelesis, Llc	Compositions and methods for modulating the intestinal microbiome
EP4493203A2 (en) *	2022-03-15	2025-01-22	Pendulum Therapeutics, Inc.	Novel microbial composition and methods of use thereof
CN114634892B (zh) *	2022-03-24	2024-07-26	浙江省农业科学院	具有降血脂作用的益生菌组合物、制备方法及设备
CN114949003B (zh) *	2022-06-08	2024-03-19	广州知易生物科技有限公司	嗜粘蛋白阿克曼菌及其应用和培养方法
CN115252651B (zh) *	2022-06-08	2024-06-07	广州知易生物科技有限公司	嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
CN114949002B (zh) *	2022-06-08	2024-03-19	广州知易生物科技有限公司	嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用
CN116115647B (zh) *	2022-06-08	2024-12-20	广州知易生物科技有限公司	嗜粘蛋白阿克曼菌在制备改善代谢综合征的药物组合物或保健品组合物中的应用
CN115804793B (zh) *	2022-06-08	2025-08-15	石家庄普维生物科技有限公司	嗜粘蛋白阿克曼菌在制备改善酒精性肝功能异常的组合物中的应用、组合物及应用
CN115463159A (zh) *	2022-09-26	2022-12-13	暨南大学附属第一医院（广州华侨医院）	一种阿克曼菌及阿克曼菌后生元在制备预防或治疗肝脏脂肪病变的药物或保健品中的应用
CN115747357A (zh) *	2022-11-15	2023-03-07	迪辅乐生物(上海)有限公司	肠道嗜粘蛋白-阿克曼氏菌的检测试剂盒及其检测方法
WO2024134035A1 (fr) *	2022-12-22	2024-06-27	Sorbonne Universite	Composition et utilisation de turicimonas muris pour le traitement de maladies métaboliques
CN116077536B (zh) *	2023-03-17	2023-11-28	微康益生菌(苏州)股份有限公司	一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用
CN116999468B (zh) *	2023-08-18	2024-11-15	善恩康生物科技（苏州）有限公司	Akkermansia muciniphila在制备预防、治疗和/或辅助治疗心血管疾病的产品中的应用
WO2025042949A2 (en) *	2023-08-22	2025-02-27	International N&H Denmark Aps	Methods and compositions for immune system regulation
CN117603884B (zh) *	2024-01-17	2024-03-26	广州同康生物科技有限公司	一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法
CN118178476A (zh) *	2024-04-03	2024-06-14	暨南大学附属第一医院（广州华侨医院）	阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用
CN118207140B (zh) *	2024-05-20	2024-09-17	微康益生菌(苏州)股份有限公司	一种具有调节血糖血脂功效的嗜粘蛋白阿克曼氏菌Akk11及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008076696A2 (en)	2006-12-18	2008-06-26	Washington University In St. Louis	The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en)	2007-08-17	2009-03-04	Nestec S.A.	Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2103226A1 (en) *	2008-03-18	2009-09-23	Friesland Brands B.V.	Long-life probiotic food product
NZ602704A (en)	2010-03-01	2015-01-30	Agronomique Inst Nat Rech	Method of diagnostic of inflammatory bowel diseases
US9173910B2 (en) *	2012-02-29	2015-11-03	The General Hospital Corporation	Compositions of microbiota and methods related thereto
WO2014075745A1 (en) *	2012-11-19	2014-05-22	Université Catholique de Louvain	Use of akkermansia for treating metabolic disorders

2012
- 2012-11-19 WO PCT/EP2012/073011 patent/WO2014075745A1/en active Application Filing
2013
- 2013-11-15 MX MX2015006234A patent/MX365835B/es active IP Right Grant
- 2013-11-15 KR KR1020217027510A patent/KR20210111871A/ko not_active Ceased
- 2013-11-15 EA EA202100040A patent/EA202100040A3/ru unknown
- 2013-11-15 KR KR1020257009967A patent/KR20250049431A/ko active Pending
- 2013-11-15 KR KR1020257009966A patent/KR20250048486A/ko active Pending
- 2013-11-15 CA CA2891758A patent/CA2891758C/en active Active
- 2013-11-15 PT PT137920062T patent/PT2919796T/pt unknown
- 2013-11-15 US US14/443,829 patent/US20150306152A1/en active Pending
- 2013-11-15 PL PL21154064.6T patent/PL3862010T3/pl unknown
- 2013-11-15 CN CN202010521429.0A patent/CN111603488B/zh active Active
- 2013-11-15 AU AU2013346726A patent/AU2013346726B2/en active Active
- 2013-11-15 JP JP2015542276A patent/JP6426616B2/ja active Active
- 2013-11-15 KR KR1020247029534A patent/KR20240137696A/ko not_active Ceased
- 2013-11-15 BR BR112015011403-2A patent/BR112015011403A2/pt not_active Application Discontinuation
- 2013-11-15 ES ES21154064T patent/ES3037446T3/es active Active
- 2013-11-15 ES ES13792006T patent/ES2871817T3/es active Active
- 2013-11-15 KR KR1020237017813A patent/KR102581171B1/ko active Active
- 2013-11-15 CN CN201380070847.0A patent/CN104918626B/zh active Active
- 2013-11-15 EA EA201500535A patent/EA037315B1/ru unknown
- 2013-11-15 KR KR1020237027149A patent/KR20230121938A/ko not_active Ceased
- 2013-11-15 WO PCT/EP2013/073972 patent/WO2014076246A1/en not_active Application Discontinuation
- 2013-11-15 ES ES21189951T patent/ES3038019T3/es active Active
- 2013-11-15 KR KR1020157016539A patent/KR102297388B1/ko active Active
- 2013-11-15 DK DK13792006.2T patent/DK2919796T3/da active
2018
- 2018-10-25 JP JP2018200556A patent/JP2019048825A/ja active Pending
2019
- 2019-05-07 US US16/285,088 patent/US20190282630A1/en not_active Abandoned
- 2019-12-10 US US16/709,232 patent/US20200155616A1/en not_active Abandoned
- 2019-12-10 US US16/709,238 patent/US20200121737A1/en not_active Abandoned
- 2019-12-20 US US16/723,720 patent/US20200237832A1/en not_active Abandoned
- 2019-12-20 US US16/723,723 patent/US20200237833A1/en not_active Abandoned
2021
- 2021-06-25 US US17/358,333 patent/US20210322489A1/en active Pending
- 2021-09-03 US US17/466,516 patent/US20210393704A1/en active Pending
2025
- 2025-05-30 US US19/224,021 patent/US20250288621A1/en active Pending
- 2025-05-30 US US19/224,071 patent/US20250288622A1/en active Pending

Also Published As

Publication number	Publication date
US20200237832A1 (en)	2020-07-30
JP6426616B2 (ja)	2018-11-21
KR20250048486A (ko)	2025-04-08
US20210322489A1 (en)	2021-10-21
WO2014075745A1 (en)	2014-05-22
CN104918626B (zh)	2020-07-07
JP2016503418A (ja)	2016-02-04
HK1215375A1 (zh)	2016-08-26
KR20230080492A (ko)	2023-06-07
AU2013346726A1 (en)	2015-06-04
US20190282630A1 (en)	2019-09-19
EA037315B1 (ru)	2021-03-11
KR20240137696A (ko)	2024-09-20
PL3862010T3 (pl)	2025-08-25
CN111603488A (zh)	2020-09-01
EA202100040A3 (ru)	2021-10-29
PT2919796T (pt)	2021-06-02
KR102581171B1 (ko)	2023-09-21
US20210393704A1 (en)	2021-12-23
US20200237833A1 (en)	2020-07-30
JP2019048825A (ja)	2019-03-28
US20200121737A1 (en)	2020-04-23
KR20150093711A (ko)	2015-08-18
ES2871817T3 (es)	2021-11-02
KR20230121938A (ko)	2023-08-21
MX2015006234A (es)	2015-10-29
EA201500535A1 (ru)	2016-03-31
US20150306152A1 (en)	2015-10-29
CN104918626A (zh)	2015-09-16
WO2014076246A1 (en)	2014-05-22
US20250288621A1 (en)	2025-09-18
AU2013346726B2 (en)	2017-11-02
BR112015011403A2 (pt)	2018-02-06
CA2891758A1 (en)	2014-05-22
CA2891758C (en)	2022-06-07
KR20250049431A (ko)	2025-04-11
KR20210111871A (ko)	2021-09-13
CN111603488B (zh)	2024-04-05
EA202100040A2 (ru)	2021-06-30
KR102297388B1 (ko)	2021-09-03
US20250288622A1 (en)	2025-09-18
ES3038019T3 (en)	2025-10-08
MX365835B (es)	2019-06-17
US20200155616A1 (en)	2020-05-21
ES3037446T3 (en)	2025-10-02
KR102297388B9 (ko)	2025-04-01

Publication	Publication Date	Title
LTC2785706I2 (lt)	2023-07-10	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
LTC2673237I2 (lt)	2024-05-27	Cirkonio silikato panaudojimas hiperkalemijos gydymui
LT2885010T (lt)	2020-04-27	Tautopatijos gydymo būdai
DK3329884T3 (da)	2021-09-13	Implanterbar indretning til behandling af glaukom
HUE043171T2 (hu)	2019-08-28	Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HUE041891T2 (hu)	2019-06-28	Berendezés ipari célokra használt víz kezelésére
HUE037048T2 (hu)	2018-08-28	Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP2866826C0 (en)	2025-08-06	COMBINATION TO TREAT INFLAMMATORY DISORDERS
EP2906208A4 (en)	2016-06-08	THERAPEUTIC TREATMENT
LT3292875T (lt)	2020-08-25	Kompozicijos ir būdai, skirti ligų gydymui
LT2928477T (lt)	2019-10-10	Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
EP2832398A4 (en)	2016-04-06	MEDICAL SHUTTER
PT3626270T (pt)	2024-01-11	Tratamento de doenças cardiovasculares
DK3040336T3 (da)	2020-06-22	Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
FR2994831B1 (fr)	2015-08-21	Prothese de main.
EP2907431A4 (en)	2015-11-04	SHOWER HEAD
IL234606A0 (en)	2014-11-30	Novel methods and composition for treatment of disease
DK2838907T3 (da)	2019-08-05	Aminosteroider til behandlingen af en ptp1b-associeret sygdom
BR112014026553A2 (pt)	2017-10-03	Fralda descartável
DK2900259T3 (da)	2020-07-13	Glycosidase-regime til behandling af infektionssygdomme
DK2892556T3 (da)	2019-08-05	Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2705847T3 (da)	2014-10-06	Sammensætning til behandling af psoriasis
DK2928454T3 (da)	2020-03-30	Triaziner til behandling af protozosygdomme
IL238592B (en)	2018-04-30	Compounds for treatment of liver diseases